ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,618.26
      -0.29%
      US Tech 100
      18,927.60
      -0.06%
      Dow Jones
      41,503.10
      -0.25%
      Brent Oil
      72.805
      0.59%
      Bitcoin
      61,990.88
      0.52%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Vanda Pharmaceuticals Inc (VNDA) Quote

      Vanda Pharmaceuticals Inc

      Vanda Pharmaceuticals Inc (VNDA)

      NASDAQ
      4.95
      0.01
      (0.20%)
      Closed September 18 4:00PM
      Delayed by 15 minutes
      4.96
      0.01
      (0.20%)
      After Hours: 6:32PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      4.96
      Bid
      4.84
      Ask
      4.97
      Volume
      574,298
      4.875 Day's Range 5.005
      3.295 52 Week Range 6.75
      Market Cap
      289.117M
      Previous Close
      4.94
      Open
      4.95
      Last Trade
      30
      @
      5.05
      Last Trade Time
      Financial Volume
      $ 2,839,796
      VWAP
      4.9448
      Average Volume (3m)
      626,967
      Shares Outstanding
      58,289,808
      Dividend Yield
      -
      PE Ratio
      115.12
      Earnings Per Share (EPS)
      0.04
      Revenue
      192.64M
      Net Profit
      2.51M

      About Vanda Pharmaceuticals Inc

      Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder... Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include Tradipitant (VLY-686), VTR-297, and VQW-765. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.vandapharma.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Vanda Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VNDA. The last closing price for Vanda Pharmaceuticals was $4.94. Over the last year, Vanda Pharmaceuticals shares have traded in a share price range of $ 3.295 to $ 6.75.

      Vanda Pharmaceuticals currently has 58,289,808 shares outstanding. The market capitalization of Vanda Pharmaceuticals is $287.95 million. Vanda Pharmaceuticals has a price to earnings ratio (PE ratio) of 115.12.

      Ask ADVFN Intelligence (AI)

      Vanda Pharmaceuticals (VNDA) Options Flow Summary

      VNDA Options Flow

      Overall Flow

      Bearish

      Net Premium

      -50k

      Calls / Puts

      0.00%

      Buys / Sells

      0.00%

      OTM / ITM

      0.00%

      Sweeps Ratio

      0.00%

      VNDA Latest News

      More News

      FeaturedElement79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership

      12 hours ago

      Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference

      Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference PR Newswire WASHINGTON, Sept. 11, 2024 WASHINGTON, Sept. 11, 2024 /PRNewswire/ -- Vanda...

      September 11 2024
      PR Newswire (US)

      Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference

      Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference PR Newswire WASHINGTON, Sept. 4, 2024 WASHINGTON, Sept. 4, 2024 /PRNewswire/ -- Vanda...

      September 04 2024
      PR Newswire (US)

      Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference

      Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference PR Newswire WASHINGTON, Aug. 29, 2024 WASHINGTON, Aug. 29, 2024 /PRNewswire/ -- Vanda Pharmaceuticals...

      August 29 2024
      PR Newswire (US)

      Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]

      August 08 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      August 08 2024
      Edgar (US Regulatory)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      August 01 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      July 31 2024
      Edgar (US Regulatory)

      Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results

      Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results PR Newswire WASHINGTON, July 31, 2024 Revenues for Q2 2024 were $50.5 million, an increase of 6% compared to Q1 2024 and an...

      July 31 2024
      PR Newswire (US)

      Form 4 - Statement of changes in beneficial ownership of securities

      July 29 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1004.965.144.84014926094.99989319CS
      4-0.34-6.415094339625.35.5254.84014575835.1543033CS
      12-1.07-17.74461028196.036.3654.84016269675.52858047CS
      261.1329.50391644913.836.753.7116031995.22610892CS
      520.24.201680672274.766.753.29512898884.79115481CS
      156-11.65-70.138470800716.6121.43993.2958253836.96623339CS
      260-8.63-63.502575423113.5921.86273.2957121069.07222234CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      OMEXOdyssey Marine Exploration Inc
      $ 1.39
      (180.07%)
      		324.51M
      PRTGPortage Biotech Inc
      $ 9.91
      (118.76%)
      		49.9M
      APLTApplied Therapeutics Inc
      $ 7.85
      (68.82%)
      		49.49M
      XCHXCHG Ltd
      $ 18.39
      (65.68%)
      		1.26M
      WBUYWeBuy Global Ltd
      $ 0.18675
      (60.99%)
      		228.66M
      GLMDGalmed Pharmaceuticals Ltd
      $ 6.8501
      (-54.64%)
      		5.79M
      KAKineta Inc
      $ 0.5691
      (-31.35%)
      		530.66k
      DTSSDatasea Inc
      $ 2.07
      (-29.59%)
      		1.28M
      CBUSCibus Inc
      $ 3.595
      (-28.95%)
      		2.25M
      BFIBurgerFi International Inc
      $ 0.1705
      (-26.98%)
      		16.23M
      OMEXOdyssey Marine Exploration Inc
      $ 1.39
      (180.07%)
      		324.51M
      NVDANVIDIA Corporation
      $ 113.37
      (-1.92%)
      		304.66M
      WBUYWeBuy Global Ltd
      $ 0.18675
      (60.99%)
      		228.66M
      SQQQProShares UltraPro Short QQQ
      $ 8.40
      (1.45%)
      		197.87M
      LUNRIntuitive Machines Inc
      $ 7.47
      (38.33%)
      		130.99M

      VNDA Discussion

      View Posts
      Monksdream Monksdream 2 weeks ago
      VNDA under $7
      👍️0
      harry crumb harry crumb 2 months ago
      Watching this closely
      👍️0
      Monksdream Monksdream 3 months ago
      VNDA under $10
      👍️0
      Monksdream Monksdream 3 months ago
      Early Barchart 100
      https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
      👍️0
      Monksdream Monksdream 3 months ago
      Over $6
      👍️0
      tw0122 tw0122 3 months ago
      Vanda acquired U.S. and Canadian rights to PONVORY® from a Johnson & Johnson Company on December 7, 2023. PONVORY® is approved by the U.S. Food and Drug Administration (FDA) and Health Canada to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease (RMS).

      In anticipation of the commercial launch of PONVORY® for RMS in the third quarter of 2024, Vanda is initiating a host of commercial activities including the creation of a specialty sales force, a prescriber awareness program and a comprehensive marketing program.
      👍️0
      harry crumb harry crumb 4 months ago
      Gonna be a winner. Patience
      👍️0
      harry crumb harry crumb 4 months ago
      Over 5$!
      👍️0
      Monksdream Monksdream 4 months ago
      VNDA under $5
      👍️0
      harry crumb harry crumb 5 months ago
      Let er rip $$$$$$$$
      👍️0
      Tiger Money Tiger Money 5 months ago
      Agreed. This could double quickly
      👍️0
      philaya philaya 5 months ago
      got this today...
      very good trades.
      👍️0
      harry crumb harry crumb 5 months ago
      This little gem could run up fast, they obviously have their science going in the right direction as the offers are there just not the price, could be a 10.00 offer in the works
      👍️0
      morokoy morokoy 5 months ago
      Shares Outstanding 57,537,499 shares
      Insider Shares 7,908,897 shares
      Insider Ownership 13.75 %
      Total Insiders 34
      👍️0
      morokoy morokoy 5 months ago
      "The dividend distribution of rights will be payable to stockholders of record as of the close of business on April 29, 2024."

      A shareholder may also receive distributions such as additional stock or stock rights in the distributing corporation; such distributions may or may not qualify as dividends.

      A shareholder may also receive distributions such as additional stock or stock rights in the distributing corporation; such distributions may or may not qualify as dividends. You should receive a Form 1099-DIV, Dividends and Distributions from each payer for distributions of at least $10.

      Guess we'll have to wait on the promised 8K.

      Additional details of the Rights Plan will be contained in a Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC"). The filing will be available on the SEC's website at www.sec.gov.
      👍️0
      harry crumb harry crumb 5 months ago
      Minimum 8$ imo
      👍️0
      MiamiGent MiamiGent 5 months ago
      Vanda Pharmaceuticals rejects takeover proposal from Future Pak
      REUTERS
      1 mins ago
      April 17 (Reuters) - Vanda Pharmaceuticals Inc (VNDA.NaE) on Wednesday said it is rejecting a takeover proposal from Future Pak, a privately-held contract manufacturer and packager of pharmaceuticals, as it significantly undervalues the company.

      (Reporting by Sriparna Roy in Bengaluru; Editing by Tasim Zahid)
      👍️0
      Monksdream Monksdream 5 months ago
      Early Barchart 100
      https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
      👍️ 1
      MiamiGent MiamiGent 5 months ago
      Probably...but I took it at 5.49
      👍️0
      Monksdream Monksdream 5 months ago
      Will it grow legs after 9:30
      👍️0
      MiamiGent MiamiGent 5 months ago
      VNDA Vol picking up..

      $5.49 +$1.44 (+35.56%)

      Volume 3,354,569

      90 DAV... 2M
      👍️0
      MiamiGent MiamiGent 5 months ago
      VNDA Here we go
      $5.3781 +$1.3281 (32.79%)

      Bid ARCX
      5.36 x 10
      Ask XNMS
      5.38 x 11
      Volume
      2,971,106
      👍️0
      MiamiGent MiamiGent 5 months ago
      VNDA Vol is good. Already @ 90 DAV
      Volume 2,056,421
      10/90-day avg. volume
      7M / 2M
      👍️0
      MiamiGent MiamiGent 5 months ago
      VNDA Good post, Laster.
      https://www.futurepak.com/
      👍️0
      Laster Laster 5 months ago
      The major question is who is Future Pak really?
      Is this a legit offer?
      Either way, company is extremely undervalued with no debt (I believe) and lots of cash.
      Large short position. Lots of selling PM at $5.
      Market does not seem to believe this offer. Sorry.
      👍️0
      MiamiGent MiamiGent 5 months ago
      VNDA Float 52.05M

      Shares Short (3/28/2024) 2.49M
      Short Ratio (3/28/2024) 2.78
      Short % of Float (3/28/2024) 5.45%
      👍️0
      MiamiGent MiamiGent 5 months ago
      VNDA
      Bid EDGX
      4.85 x 3
      Ask EDGX
      4.88 x 3

      Volume
      1,790,654
      Avg Vol (10 day) 6.63M
      👍️0
      MiamiGent MiamiGent 5 months ago
      Vanda Pharmaceuticals
      Closed .01 (-0.25%)

      Pre-market
      $5.15 +1.10 (+27.16%)
      As of Apr-17-2024 7:23:52 AM ET
      Bid x size $5.14 x 1
      Ask x size $5.16 x 3
      👍️0
      MiamiGent MiamiGent 5 months ago
      VNDA In 5.12. Let's see, said the blind man.
      👍️0
      MiamiGent MiamiGent 5 months ago
      Vanda Pharmaceuticals jumps 38% on Future Pak's latest buy offer
      Apr. 17, 2024 6:41 AM ETVanda Pharmaceuticals Inc. (VNDA) Stock
      👍️0
      MiamiGent MiamiGent 5 months ago
      What's the news?
      👍️0
      Awl416 Awl416 5 months ago
      Damn
      👍️0
      Monksdream Monksdream 5 months ago
      Will it grow legs after 9:30
      👍️0
      Monksdream Monksdream 6 months ago
      Will it grow legs after 9:30
      👍️0
      tknuncle tknuncle 7 months ago
      I have been acquiring since $3.90. I wish that I would have waited longer lol but, like what I see with VNDA. Was going to grab the last of my starter position soon. GLTA
      👍️0
      weedtrader420 weedtrader420 8 months ago
      FDA Approve
      👍️0
      Triple nickle Triple nickle 9 months ago
      Fda accepts new drug application for tradipitant in the after hours today
      👍️ 1
      jgrabar jgrabar 2 years ago
      $VNDA -On May 19, 2022, Vanda Pharmaceuticals agreed to settle a securities fraud class action complaint (the “Complaint”) for $11.5 Million. https://grabarlaw.com/the-latest/vanda-pharmaceuticals-investigation/
      👍️0
      RNsidersbuying RNsidersbuying 4 years ago
      VNDA 12.34 - FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome

      https://ih.advfn.com/stock-market/NASDAQ/vanda-pharmaceuticals-VNDA/stock-news/83807075/fda-approves-hetlioz-tasimelteon-for-the-treatmen
      👍️0
      XenaLives XenaLives 4 years ago
      Everything would be a lot better if the govt. would just let doctors treat COVID like another flu bug. The drama is getting old.
      👍️0
      Peepson Peepson 4 years ago
      Yo, this thing is going to trade sideways for a while. They have a drug that could help with covid but so does every other pharma company. Its a safe hold imo but nothing will happen fast i don't think
      👍️0
      XenaLives XenaLives 4 years ago
      What's up? Doesn't seem to be much interest. I was looking at the chart but haven't found much on the company yet.

      👍️0
      otcmoneydoubler otcmoneydoubler 4 years ago
      LOL. VNDA GOT NEWS TODAY. SO WHAT DD HAVE YOU GOT TO SHARE?
      👍️0
      Peepson Peepson 4 years ago
      Yo, does anyone still follow this board. I might have some interesting dd to share.
      👍️0
      bezen bezen 8 years ago
      https://finance.yahoo.com/news/jefferies-5-top-biotech-stocks-133534894.html
      👍️0
      Coz Mabluda Coz Mabluda 8 years ago
      Brett Jensen. SA article re VNDA. Expects positive analyst's review.

      Vanda Pharmaceuticals (NASDAQ:VNDA) posted solid third quarter results on Thursday. Instead of losing a dime a share as expected, the company posted a profit of 11 cents a share. Revenue was also up more than 35% from the same period a year ago. The company now looks like it could be profitable in FY2017. I expect some positive analyst commentary on this name by analysts over the next week. Vanda has a solid pipeline and over $140 million in cash and marketable securities on the balance sheet. One has to like the company's growth trajectory and the concern seems undervalued with just a $600 million market capitalization.



      👍️0
      stocktrademan stocktrademan 8 years ago
      fast and steady profit scan VNDA bullish 16.64



      normal chart


      log chart

      👍️0
      ClearlyStocks ClearlyStocks 8 years ago
      VNDA $16.74
      👍️0
      ClearlyStocks ClearlyStocks 8 years ago
      $VNDA $16 from $14 now
      👍️0
      nyctraydr nyctraydr 8 years ago
      Where Things Stand For Vanda Pharmaceuticals In Fanapt Patent Suit http://marketexclusive.com/things-stand-vanda-pharmaceuticals-inc-nasdaqvnda-fanapt-patent-suit/24951/?icd1
      👍️0

      Your Recent History

      NASDAQ
      VNDA
      Vanda Pharmaceuticals
      Delayed Upgrade Clock